The current system is advantageous for multinational companies, and many domestic companies welcome reorganization. The system for extending the duration of drug patents is expected to be reorganized. The Korean Intellectual Property Office established a related TF and prepared an improvement plan, and recently inquired about opinions in the pharmaceutical bio industry.

The direction of improvement of the system, which has sharp interests between the original and generic companies, is largely in international harmony with the United States and Europe.
◆Xeljanz patent period, 27 years in Korea, 25 years in the U.S. and Europe...From institutional differences

The Korean Intell